The Micro C is highly flexible in extremity surgeries
The Micro C Emitter is mobile, fast, light weight, and safe
Evan Ruff, Chief Executive Officer & Co-founder
OXOS founders, inventors of Micro C, world’s first handheld fluoroscopic system, access healthcare industry leaders at MedTech Innovator Summit and Conference
OXOS welcomes the opportunity to present our key success factors to healthcare industry leaders - intellectual property, product development, regulatory submissions, market opportunity, and financing.”
— Evan Ruff, CEO & Co-Founder of OXOS Medical
ATLANTA, GEORGIA, UNITED STATES, June 25, 2020 /EINPresswire.com/ -- OXOS Medical was selected by MedTech Innovator, the premier nonprofit accelerator in the medical technology industry, to join a cohort of 50 early-stage companies in a highly competitive field of the most transformative device, diagnostic, and digital health technologies from around the globe. At the June 25th, 2020 MedTech Innovator Summit, OXOS Medical Co-founders Dr. Gregory Kolovich, Chief Medical Officer and Evan Ruff, CEO, will engage with leading manufacturers, providers, potential customers, and investors through online events and workshops. They will then present during the Showcase of the October 5-7 MedTech Innovator Conference currently planned for Toronto, Canada. Dr. Kolovich remarked, “Achieving this distinction as a leading early-stage medical technology company as we approach commercial market entry is confirmation for the OXOS Medical team, partners, and investors that our development of advanced orthopedic imaging devices and software has significant value.”
Evan Ruff noted, "OXOS welcomes the opportunity to present our key success factors to healthcare industry leaders - intellectual property, product development, regulatory submissions, market opportunity, and financing.“ Criteria used by MedTech Innovator judges to evaluate OXOS Medical were based on value, execution, and momentum strengths. Value criteria were: product, customer validation, business model and healthcare economics, competition, intellectual property, market opportunity, and patient benefit. Execution criteria were: team strength and execution, development plan, responsiveness to feedback, freedom to operate, regulatory and clinical burden, existing funding, and resources to execute. Momentum criteria were: stage of development, evidence, time to market, traction and sales, partnerships and relationships, time to key milestones, and upcoming funding.
Murem Sharpe
OXOS Medical
+1 912-247-4255 email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
OXOS Medical (OXOS) puts the future of x-ray in your hands. OXOS Micro C, the first handheld dynamic digital radiography (DDR) x-ray system, is faster, safer, and smarter and is available now. The company entered the $50 billion U.S. diagnostic radiology market with the U.S. Food and Drug Administration (FDA) 510(k) clearance of its Micro C Medical Imaging System. The company will develop and launch additional products utilizing the OXOS Platform—a system for on-demand image management, telehealth collaboration, and delivery of artificial intelligence (AI) diagnostics, among other workloads. Additional information available at: https://oxos.com/ or info@oxos.com
OXOS and Micro C are registered trademarks of OXOS Medical, Inc.